The global western blotting market size was estimated to be USD 1.25 billion in 2023 and is expected to reach at USD 2.61 billion by 2033 with a CAGR of 6.95% during the forecast period 2023-2033. Increasing research activities, advancements in proteomics research, diagnostic applications, technological advancements, a growing biopharmaceutical industry, and increasing investments in life sciences research are some key factors driving the market.
Western blotting methods and equipment have improved in sensitivity, specificity, and usability. For instance, the introduction of precast gels, automated blotting equipment, and improved imaging technologies has streamlined and improved the Western blotting procedure. These scientific developments draw laboratories and researchers, which stimulates commercial expansion. For instance, New England Biolabs introduced a new Western Blotting kit on January 25, 2023, which comprises a new antibody and a new detection reagent. The kit's goal is to increase the results of Western Blotting's sensitivity and specificity.
By type, consumables was the highest revenue-grossing segment in the global western blotting market in 2022 owing to rising usage of consumables in western blotting technique and surge in use of reagents, growing mergers & acquisitions within key market players. For instance, in September 2021, PerkinElmer Inc has completed the acquisition of BioLegend, a prominent supplier of life science antibodies and reagents, which includes primary antibodies and secondary reagents for western blotting. This acquisition strengthens PerkinElmer's current western blotting product lineup. Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for instruments in western blotting technique.
By application, biomedical research was the highest revenue-grossing segment in the global western blotting market in 2022 owing to the rising funding for research in the filed of proteomics and growing research & development activities. Additionally, Disease diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for disease diagnostic testing. For instance, in January 2022, Bio-Techne Corporation, under its brand ProteinSimple, has revealed the launch of Stellar NIR/IRTM Detection Modules for Jess. These advanced fluorescent modules enable the detection of proteins with low abundance and facilitate the simultaneous multiplexing of multiple analytics within a single detection lane.
By end user, academic and research institutes was the highest revenue-grossing segment in the global western blotting market in 2022 owing to increasing government investments for research & development activities. Additionally, pharmaceutical and biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the rising launch of new products. For instance, in April 2021, Bio-Techne Corporation, through its brand ProteinSimple, has unveiled Abby, a state-of-the-art chemiluminescence system that automates conventional Western blotting. This new member of the Simple Western product line provides exceptional sensitivity at the picogram level using chemiluminescence detection. Additionally, Abby allows for sequential immunoassays utilizing RePlex.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, increasing development of western blotting products, growing investment for research by market players, and rising launch of innovative products. For instance, in October 2020, Bio-Techne Corporation has introduced a SARS-CoV-2 Multi Antigen Serology Module designed for the Jess and Wes Simple Western automated western blotting systems. This novel serology assay expedites COVID-19 research and vaccine development by swiftly analyzing the human immune response to various SARS-CoV-2 antigens. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in research funding, rising focus on personalized medicine, and increasing initiatives such as mergers & acquisitions by major market players. For instance, in August 2021, Abcam Plc has completed the acquisition of BioVision Inc, a prominent supplier of biochemical and cell-based assays. BioVision Inc is known for its extensive range of products, including recombinant proteins, antibodies, enzymes, and biochemical compounds utilized in immunoassay technologies like western blotting.
Western blotting methods and equipment have improved in sensitivity, specificity, and usability. For instance, the introduction of precast gels, automated blotting equipment, and improved imaging technologies has streamlined and improved the Western blotting procedure. These scientific developments draw laboratories and researchers, which stimulates commercial expansion. For instance, New England Biolabs introduced a new Western Blotting kit on January 25, 2023, which comprises a new antibody and a new detection reagent. The kit's goal is to increase the results of Western Blotting's sensitivity and specificity.
By type, consumables was the highest revenue-grossing segment in the global western blotting market in 2022 owing to rising usage of consumables in western blotting technique and surge in use of reagents, growing mergers & acquisitions within key market players. For instance, in September 2021, PerkinElmer Inc has completed the acquisition of BioLegend, a prominent supplier of life science antibodies and reagents, which includes primary antibodies and secondary reagents for western blotting. This acquisition strengthens PerkinElmer's current western blotting product lineup. Additionally, Instruments is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for instruments in western blotting technique.
By application, biomedical research was the highest revenue-grossing segment in the global western blotting market in 2022 owing to the rising funding for research in the filed of proteomics and growing research & development activities. Additionally, Disease diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for disease diagnostic testing. For instance, in January 2022, Bio-Techne Corporation, under its brand ProteinSimple, has revealed the launch of Stellar NIR/IRTM Detection Modules for Jess. These advanced fluorescent modules enable the detection of proteins with low abundance and facilitate the simultaneous multiplexing of multiple analytics within a single detection lane.
By end user, academic and research institutes was the highest revenue-grossing segment in the global western blotting market in 2022 owing to increasing government investments for research & development activities. Additionally, pharmaceutical and biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the rising launch of new products. For instance, in April 2021, Bio-Techne Corporation, through its brand ProteinSimple, has unveiled Abby, a state-of-the-art chemiluminescence system that automates conventional Western blotting. This new member of the Simple Western product line provides exceptional sensitivity at the picogram level using chemiluminescence detection. Additionally, Abby allows for sequential immunoassays utilizing RePlex.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players, increasing development of western blotting products, growing investment for research by market players, and rising launch of innovative products. For instance, in October 2020, Bio-Techne Corporation has introduced a SARS-CoV-2 Multi Antigen Serology Module designed for the Jess and Wes Simple Western automated western blotting systems. This novel serology assay expedites COVID-19 research and vaccine development by swiftly analyzing the human immune response to various SARS-CoV-2 antigens. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in research funding, rising focus on personalized medicine, and increasing initiatives such as mergers & acquisitions by major market players. For instance, in August 2021, Abcam Plc has completed the acquisition of BioVision Inc, a prominent supplier of biochemical and cell-based assays. BioVision Inc is known for its extensive range of products, including recombinant proteins, antibodies, enzymes, and biochemical compounds utilized in immunoassay technologies like western blotting.
Segmentation: Western Blotting Market Report 2022-2033
Western Blotting Market Analysis & Forecast by Type 2022-2033 (Revenue USD Bn)
- Consumables
- Instruments
Western Blotting Market Analysis & Forecast by Application 2022-2033 (Revenue USD Bn)
- Biomedical Research
- Disease Diagnostics
- Agriculture and Food Testing
Western Blotting Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Bn)
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Clinical Laboratories
- Contract Research Organizations (CROs)
Western Blotting Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Western Blotting: Type Estimates & Trend Analysis
8. Western Blotting: Application Estimates & Trend Analysis
9. Western Blotting: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Western Blotting Market
12. Europe Global Western Blotting Market
13. Asia Pacific Global Western Blotting Market
14. Latin America Global Western Blotting Market
15. MEA Global Western Blotting Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Merck KGaA (MilliporeSigma)
- GE Healthcare
- PerkinElmer Inc.
- Advansta Inc.
- Cell Signaling Technology Inc.
- LI-COR
- Biosciences
- Abcam plc
- Bio-Techne Corporation
- Agilent Technologies Inc.
- BioVision Inc.
- Santa Cruz Biotechnology Inc.
- Rockland Immunochemicals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 1.25 Billion |
| Forecasted Market Value ( USD | $ 2.61 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
